MBRX - Moleculin Biotech, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.26
-0.06 (-4.55%)
At close: 3:58PM EDT
Stock chart is not supported by your current browser
Previous Close1.32
Open1.32
Bid0.00 x 1000
Ask0.00 x 3200
Day's Range1.25 - 1.33
52 Week Range1.25 - 3.34
Volume184,517
Avg. Volume115,391
Market Cap34.152M
Beta (3Y Monthly)-0.70
PE Ratio (TTM)N/A
EPS (TTM)-0.57
Earnings DateNov 12, 2018 - Nov 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
Trade prices are not sourced from all markets
  • GlobeNewswire8 days ago

    Moleculin Announces New Data Discovery Confirming Significant Increase in Potential to Starve Cancerous Tumors

    Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that new data relating to its molecule WP1122 will be presented at the upcoming Society for Neuro-Oncology Annual Scientific Meeting. Walter Klemp, Moleculin’s Chairman and CEO added, “Metabolic inhibition of tumors is conceptually a very important approach, and we believe we have a clear translational focus.

  • GlobeNewswirelast month

    Moleculin’s Brain Cancer Drug Candidate Begins Patient Dosing at Clinical Trial Being Conducted at MD Anderson

    In the ongoing challenge to combat the almost always deadly brain cancers, namely Glioblastoma and melanoma metastasized to the brain, the pharmaceutical company Moleculin Biotech, Inc., (MBRX) has initiated a Phase 1 clinical trial of a new first-in-class cancer drug candidate, a small molecule compound discovered by Prof. Waldemar Priebe at  The University of Texas MD Anderson Cancer Center and known as WP1066. The compound has been shown in animal models to both inhibit an important cell signaling protein STAT3 that is involved in cell growth and proliferation and considered critical to tumor development, while also stimulating an immune response.  The first glioblastoma patient has received the initial doses of WP1066, which were apparently well tolerated, in the physician-sponsored IND (investigational new drug) study at MD Anderson Cancer Center.

  • GlobeNewswire2 months ago

    Moleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended June 30, 2018

    Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center, today announced its financial results for the second quarter ended June 30, 2018. Additionally, the Company announced potential upcoming milestones and recent corporate developments. Walter Klemp, Chairman and CEO of Moleculin, said, “During the second quarter, and the first half of 2018, we continued to make measurable progress in achieving important milestones in our three core disruptive technologies and six oncology drug candidates.

  • GlobeNewswire2 months ago

    Moleculin Seeks Approval from Polish Regulatory Agency for Skin Cancer Clinical Trial

    HOUSTON, Aug. 09, 2018-- Moleculin Biotech, Inc.,, a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The ...

  • GlobeNewswire3 months ago

    Moleculin Announces Enrollment Opens for Brain Tumor Trial of WP1066

    Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced enrollment has opened for a physician-sponsored clinical trial of WP1066 for the treatment of glioblastoma and brain metastases in adults. “We have been eagerly awaiting the beginning of this physician sponsored clinical trial,” commented Walter Klemp, Chairman and CEO of Moleculin.

  • Benzinga4 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Winnebago Industries, Inc. (NYSE: WGO ) stock was ...

  • ACCESSWIRE5 months ago

    Nektar Therapeutics and Three Additional Biotech Stocks on Our Research Desk’s Radar

    Stock Research Monitor: MBRX, OGEN, and OTIC LONDON, UK / ACCESSWIRE / May 29, 2018 / If you want a free Stock Review on NKTR sign up now at www.wallstequities.com/registration . On Friday, May 25, 2018, ...

  • Who Owns Most Of Moleculin Biotech Inc (NASDAQ:MBRX)?
    Simply Wall St.5 months ago

    Who Owns Most Of Moleculin Biotech Inc (NASDAQ:MBRX)?

    Today, I will be analyzing Moleculin Biotech Inc’s (NASDAQ:MBRX) recent ownership structure, an important but not-so-popular subject among individual investors. The impact of a company’s ownership structure affects both itsRead More...

  • Marketwired6 months ago

    Moleculin Announces New Data for Immuno-Stimulating Drug to be Presented at International Conference

    Moleculin Biotech, Inc., , a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System......

  • ACCESSWIRE6 months ago

    Wired News – Spectrum Pharma Reported Update Data from MD Anderson’s Phase-2 Data Assessing Poziotinib in EGFR Exon 20 Mutant NSCLC Patients

    Stock Monitor: Moleculin Biotech Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 12, 2018 / Active-Investors.com has just released a free research report on Spectrum Pharma, Inc. (NASDAQ: SPPI ...

  • Marketwired6 months ago

    Moleculin Announces Patients Treated in FDA Approved Phase I/II Annamycin Clinical Trial

    Moleculin Biotech, Inc., , a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System......

  • Marketwired7 months ago

    Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2017

    Moleculin Biotech, Inc. , a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System......

  • Marketwired7 months ago

    Moleculin Enters Agreement with Seidman Cancer Center to Conduct Leukemia Clinical Trials

    Moleculin Biotech, Inc., , a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System......

  • Marketwired7 months ago

    Moleculin Announces Grant-Funded Collaboration to Expand Understanding of New Discovery

    Moleculin Biotech, Inc. , a clinical stage pharmaceutical company focused on the development of oncology drug candidates, some of which are based on license agreements with The University of Texas System......